Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies. (Q38983579)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27752945%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

review article

1 reference

title

Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27752945%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27752945%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Henrik Walter

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27752945%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

3

Eva J Brandl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27752945%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

publication date

1 December 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27752945%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27752945%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27752945%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

page(s)

1169-1189

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27752945%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27752945%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40263-016-0385-9

25 March 2020

exact match

0 references

cites work

Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Early switching strategies in antidepressant non-responders: current evidence and future research directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genetic epidemiology of major depression: review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Contribution of common genetic variants to antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Imaging genetics: implications for research on variable antidepressant drug response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Frontocingulate dysfunction in depression: toward biomarkers of treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

A meta-analytic study of changes in brain activation in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

A systematic review of relations between resting-state functional-MRI and treatment response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genetics and personalized medicine in antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genome-wide association studies in pharmacogenomics of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Polymorphisms in serotonergic pathways influence the outcome of antidepressant therapy in psychiatric inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Antidepressant response and the serotonin transporter gene-linked polymorphic region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

SERT and NET polymorphisms, temperament and antidepressant response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Escitalopram efficacy in depression: a cross-ethnicity examination of the serotonin transporter promoter polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

SLC6A4 variation and citalopram response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Serotonin transporter genotype and function in relation to antidepressant response in Koreans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Serotonin transporter gene promotor polymorphism (5-HTTLPR) associations with number of psychotropic medication trials in a tertiary care outpatient psychiatric consultation practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Effects of Depression and Serotonergic Antidepressants on Bone: Mechanisms and Implications for the Treatment of Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Systematic review and meta-analysis of serotonin transporter genotype and discontinuation from antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The pharmacogenetics of antidepressant-induced mania: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Pharmacogenomics of antidepressant induced mania: a review and meta-analysis of the serotonin transporter gene (5HTTLPR) association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Clinical risk factors and serotonin transporter gene variants associated with antidepressant-induced mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Harm avoidance moderates the influence of serotonin transporter gene variants on treatment outcome in bipolar patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional G×G and G×E differences in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Pharmacogenetics in major depression: a comprehensive meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Serotonin transporter gene polymorphisms and sertraline response in major depression patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The functional serotonin 1a receptor promoter polymorphism, rs6295, is associated with psychiatric illness and differences in transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Interaction of 5-HTT and HTR1A gene polymorphisms in treatment responses to mirtazapine in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

No effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

HTR2A gene variation is involved in antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Functional genomics of serotonin receptor 2A (HTR2A): interaction of polymorphism, methylation, expression and disease association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Identifying genetic loci associated with antidepressant drug response with drug-gene interaction models in a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genetic predictors of response to antidepressants in the GENDEP project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Analysis of 34 candidate genes in bupropion and placebo remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genetic predictors of antidepressant side effects: a grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Tryptophan hydroxylase gene associated with paroxetine antidepressant activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Investigation of serotonin-related genes in antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

TPH, SLC6A2, SLC6A3, DRD2 and DRD4 Polymorphisms and Neuroendocrine Factors Predict SSRIs Treatment Outcome in the Chinese Population with Major Depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

BDNF - a key transducer of antidepressant effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Brain-derived neurotrophic factor Val66Met polymorphism association with antidepressant efficacy: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genes involved in neuroplasticity and stressful life events act on the short-term response to antidepressant treatment: a complex interplay between genetics and environment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Possible associations of NTRK2 polymorphisms with antidepressant treatment outcome: findings from an extended tag SNP approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The role of BDNF, NTRK2 gene and their interaction in development of treatment-resistant depression: data from multicenter, prospective, longitudinal clinic practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Effects of BDNF polymorphisms on antidepressant action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

BDNF Val66Met genotype determines hippocampus-dependent behavior via sensitivity to glucocorticoid signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

No support for a role for BDNF gene polymorphisms rs11030101 and rs61888800 in major depressive disorder or antidepressant response in patients of Finnish origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Family-based association of FKBP5 in bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Associations Between Self-Reported and Objectively Recorded Early Life Stress, FKBP5 Polymorphisms, and Depressive Symptoms in Midlife

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

FKBP5 and resistant attachment predict cortisol reactivity in infants: gene-environment interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

A new anti-depressive strategy for the elderly: ablation of FKBP5/FKBP51.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Glucocorticoid receptor and FKBP5 expression is altered following exposure to chronic stress: modulation by antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Selective inhibitors of the FK506-binding protein 51 by induced fit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

FKBP5 polymorphisms and antidepressant response in geriatric depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genetic variants in FKBP5 affecting response to antidepressant drug treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

DNA sequence variants of the FKBP5 gene are associated with unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Variation in GNB3 predicts response and adverse reactions to antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

SSRIs antidepressant activity is influenced by G beta 3 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Association of a human G-protein beta3 subunit variant with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Influence of GNB3 C825T polymorphism on the efficacy of antidepressants in the treatment of major depressive disorder: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The role of GRIK4 gene in treatment-resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder--a European multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Lack of influence of DAT1 and DRD2 gene variants on antidepressant response in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The role of single nucleotide polymorphism of D2 dopamine receptor gene on major depressive disorder and response to antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Sequence polymorphisms of MC1R gene and their association with depression and antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Resistance to antidepressant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Monoamine oxidase A variant influences antidepressant treatment response in female patients with Major Depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Pharmacogenetics of antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

European Group for the Study of Resistant Depression (GSRD)--where have we gone so far: review of clinical and genetic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Suicidal ideation during antidepressant treatment: do genetic predictors exist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genetic differences in cytochrome P450 enzymes and antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

CYP2C19 variation and citalopram response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Neither cytochrome P450 family genes nor neuroendocrine factors could independently predict the SSRIs treatment in the Chinese Han population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Patients with difficult-to-treat depression do not exhibit an increased frequency of CYP2D6 allele duplication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Will a new genotyping test help the clinician predict response to antidepressant drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Association between ABCB1 Polymorphisms and Antidepressant Treatment Response in Taiwanese Major Depressive Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The Influence of C3435T Polymorphism of the ABCB1 Gene on Genetic Susceptibility to Depression and Treatment Response in Polish Population - Preliminary Report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Association between genetic variation in the ABCB1 gene and switching, discontinuation, and dosage of antidepressant therapy: results from the Rotterdam Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

MDR1 in paroxetine-induced sexual dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

ABCB1 C3435T polymorphism is associated with susceptibility to major depression, but not with a clinical response to citalopram in a Turkish population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Investigation of polymorphism in the MDR1 gene and antidepressant-induced mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genome-wide association studies of antidepressant outcome: a brief review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

A genomewide association study of citalopram response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

A genome-wide association study of a sustained pattern of antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

A genome-wide association study of antidepressant response in Koreans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genome-wide association study of antidepressant treatment-emergent suicidal ideation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Functional neuroanatomy of emotion: a meta-analysis of emotion activation studies in PET and fMRI

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Emotional valence modulates brain functional abnormalities in depression: evidence from a meta-analysis of fMRI studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Functional neuroimaging of major depressive disorder: a meta-analysis and new integration of base line activation and neural response data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Gray matter abnormalities in Major Depressive Disorder: a meta-analysis of voxel based morphometry studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Antidepressants normalize the default mode network in patients with dysthymia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Resting state functional connectivity and treatment response in late-life depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Association of thalamic hyperactivity with treatment-resistant depression and poor response in early treatment for major depression: a resting-state fMRI study using fractional amplitude of low-frequency fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The effect of the serotonin transporter polymorphism (5-HTTLPR) on amygdala function: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Amygdala responses to quetiapine XR and citalopram treatment in major depression: the role of 5-HTTLPR-S/Lg polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The impact of 5-HTTLPR on acute serotonin transporter blockade by escitalopram on emotion processing: preliminary findings from a randomised, crossover fMRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Impact of 5-HTTLPR on SSRI serotonin transporter blockade during emotion regulation: A preliminary fMRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Allelic variation in 5-HTTLPR and the effects of citalopram on the emotional neural network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Endocannabinoid signaling as a synaptic circuit breaker in neurological disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Relevance of neuropeptide Y (NPY) in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Neuropeptide Y (NPY) gene: Impact on emotional processing and treatment response in anxious depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Cytokines: abnormalities in major depression and implications for pharmacological treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Val66Met BDNF genotypes in melancholic depression: effects on brain structure and treatment outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

BDNF val66met polymorphism, white matter abnormalities and remission of geriatric depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Finding the Elusive Psychiatric "Lesion" With 21st-Century Neuroanatomy: A Note of Caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Intermediate phenotypes and genetic mechanisms of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

The endophenotype concept in psychiatric genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Deep brain stimulation for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

A randomized trial of rTMS targeted with MRI based neuro-navigation in treatment-resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0385-9

CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response

21 January 2018

1 reference

12 December 2020

Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study

1 reference

12 December 2020

Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment

1 reference

12 December 2020

Clinical and economic impact of non-adherence to antidepressants in major depressive disorder: A systematic review

1 reference

12 December 2020

Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors

1 reference

12 December 2020

From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment

1 reference

12 December 2020

CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure

1 reference

12 December 2020

Heat-shock protein-70 genes and response to antidepressants in major depression

1 reference

12 December 2020

Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients

1 reference

12 December 2020

Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder.

1 reference

12 December 2020

Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy

1 reference

12 December 2020

Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression

1 reference

12 December 2020

Treatment-resistant depression.

1 reference

12 December 2020

ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment.

1 reference

12 December 2020

ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline

1 reference

12 December 2020

Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample

1 reference

12 December 2020

The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression

1 reference

12 December 2020

Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment

1 reference

12 December 2020

Serotonin transporter polymorphism in major depressive disorder (MDD), psychiatric disorders, and in MDD in response to stressful life events: causes and treatment with antidepressant

1 reference

12 December 2020

Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders

1 reference

12 December 2020

Association of the COMT val158met variant with antidepressant treatment response in major depression

1 reference

12 December 2020

Association between the 5-HT1A receptor gene polymorphism (rs6295) and antidepressants: a meta-analysis

1 reference

12 December 2020

5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression.

1 reference

12 December 2020

The cannabinoid CB1receptor and the endocannabinoid anandamide: possible antidepressant targets

1 reference

12 December 2020

Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter.

1 reference

12 December 2020

Serotonin Transporter Polymorphism (5-HTTLPR) and Citalopram Effectiveness in Iranian Patients with Major Depressive Disorder

1 reference

12 December 2020

10.1007/S40263-016-0385-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27752945%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference